Abstract
Agents that interfere with the renin-angiotensin system (RAS) may ameliorate progressive renal injury, particularly in a setting where intrarenal RAS activity appears to be elevated. Whether RAS antagonists affect renal disease progression when intrarenal RAS activity is not increased is unclear. In this study, therefore, the effects of the angiotensin II receptor antagonist losartan on glomerular and tubulointerstitial injury were investigated in obese Zucker rats (OZR), an experimental model of progressive renal disease characterized by reduced intrarenal renin content and reduced plasma renin activity. Losartan (100 or 200 mg/L of drinking water) was administered to OZR beginning at 26 wk of age, when renal disease was established. At 38 and 44 wk of age, losartan-treated OZR demonstrated significant (P < 0.05) dose-related decreases in systolic blood pressure, compared with blood pressures in untreated, control OZR. Despite the reductions in blood pressure, losartan had no significant effects on albuminuria or glomerular or tubulointerstitial injury. At 44 wk of age, the percentage (mean +/- SE) of glomeruli with sclerosis was 51 +/- 11, 49 +/- 9, and 39 +/- 14% in control OZR, low-dose (100 mg/L) losartan-treated OZR, and ...Continue Reading
Citations
May 7, 1999·Kidney International·T SugiuraM Hori
Jun 25, 2002·The Journal of Laboratory and Clinical Medicine·Takayuki OtaYasuhide Nakashima
Jun 5, 2001·Japanese Journal of Pharmacology·M NodaY Imura
Oct 24, 2002·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Toshiyuki TanakaHidetoshi Yamanaka
May 20, 2004·Kidney International·Jorge Eduardo ToblliPatricia Pagano
Apr 20, 2005·Annals of Anatomy = Anatomischer Anzeiger : Official Organ of the Anatomische Gesellschaft·Marina AunapuuAndres Arend
Nov 25, 2005·Journal of Cardiovascular Pharmacology·Gaëlle NaeltenMing Lo
Jul 25, 2003·Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie·Dorothea AppenrothChristian Fleck
Mar 7, 2006·European Journal of Pharmacology·Philip JaniakJean-Marc Herbert
Mar 1, 1997·Kidney International·H GeigerH H Neumayer
Aug 19, 2007·American Journal of Physiology. Heart and Circulatory Physiology·David W SteppDavid M Pollock
Jan 8, 2008·Current Hypertension Reports·Jochen Reiser, Peter Mundel
Aug 14, 2001·Obesity Research·F T StevensonJ S Stern
Mar 26, 2010·Pharmaceuticals·Talma RosenthalAriela Alter